Premaitha will issue Thermo Fisher warrants over 28,938,797 new ordinary shares and a second tranche of warrants in 2018.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
According to John Zhang, founder and CEO of the New Hope Fertility Center, universal PGS will likely increase success rates of IVF further.
A study by researchers in Italy found that preimplantation genetic diagnosis and screening combined led to more successful pregnancies per transfer but fewer women had embryos transferred.
At last week's ESHG annual meeting, three quality assessment providers discussed best practice guidelines and results from a pilot NIPT quality assessment scheme.
In a report made public this week, the French National Authority for Health recommended NIPT if first semester screening indicated a risk between 1 in 51 and 1 in 1,000.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.